SK Chemicals to introduce Toray's TRK-820

Published: 2006-06-30 06:57:00

Updated: 2006-06-30 06:57:00

SK Chemicals announced on June 27 that it has concluded a licensing agreement with Toray Inc. of Tokyo, Japan, for the introduction of TRK-820 (nalfurafine HCl).

TRK-820 is a highly selective kappa opioid receptor agonist that has completed multiple Phase II studies for the treatment of uremic...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK